Heilongjiang Tianlong Pharmaceutical, Inc. Obtains SFDA Approval to Produce Two New Drugs
Oxymetazoline Hydrochloride Nasal Drops is approved for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine Eye Drops is approved for the treatment of acute and chronic conjunctivitis. The incidences of these diseases in China are extremely high. This is especially true in regions with colder weather as well as coastal regions.
These approvals bring the total number of China Sky One's products for externally used drugs to 49 and the total marketed products to 98, making China Sky One the company with the most comprehensive pharmaceutical product portfolio in China. The Company is still aggressively seeking approval for other drugs with large market potential. By the end of 2008, the Company will have a total 38 new drugs submitted to the SFDA approval.
"Most of the pharmaceutical companies that make these two products in China do not have strong distribution channels. China Sky One will be able to quickly commercialize these two drugs and capture at least 10% of the market share by leveraging our extensive sales network and experienced management team," said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc. "We believe that the commercialization of these two products will provide a steady revenue for China Sky One and further improve our profitability in the years ahead."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a China based company engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company and Harbin First Bio-Engineering Company Limited the Company manufactures and distributes over-the-counter pharmaceutical products as its primary revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Additional statements that are necessarily forward-looking in nature also include, without limitation, statements relating to our research and development activities, expected revenues or sales margins, results of recent acquisitions and our ability to increase sales and expand our presence in the global market place, and risks or uncertainties relating to PRC socioeconomic issues. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. The Company cannot provide any assurance that it will be able to establish listing of its securities on any national or regional securities exchange or market system. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the inability of the company to meet listing standards of an exchange, risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners both in China and throughout the world and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
China Sky One Medical, Inc. Mr. Liao Xiaoqing, CFO Tel: +86-1591-067-2198 Email: tdrhan@163.com
CCG Elite Investor Relations Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com Website: http://www.ccgelite.com
Source: China Sky One Medical, Inc.